

Renal Cell Carcinoma / Melanoma Treatment

Reference Number: RDF1313-23

Date of Response: 15/03/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

I have a freedom of information request regarding the treatment of renal cell carcinoma and melanoma. Could you please answer the following questions:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- *Avelumab + Axitinib*
- *Axitinib*
- *Cabozantinib*
- *Everolimus*
- *Lenvatinib + Everolimus*
- *Nivolumab*
- *Nivolumab + Cabozantinib*
- *Nivolumab + Ipilimumab*
- *Pazopanib*
- *Pembrolizumab + Axitinib*
- *Pembrolizumab + Lenvatinib*
- *Pembrolizumab monotherapy*
- *Radiotherapy only*
- *Sunitinib*
- *Temsirolimus*
- *Tivozanib*
- *Other active systemic anti-cancer therapy*
- *Palliative care only*

Answer: Please see table overleaf. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.

Treatment	Total
<i>Avelumab + Axitinib</i>	8
<i>Axinitib</i>	Nil
<i>Cabozantinib</i>	19
<i>Everolimus</i>	≤5
<i>Lenvatinib + Everolimus</i>	Nil
<i>Nivolumab</i>	20
<i>Nivolumab + Cabozantinib</i>	Nil
<i>Nivolumab + Ipilimumab</i>	≤5
<i>Pazopanib</i>	≤5
<i>Pembrolizumab + Axitinib</i>	Nil
<i>Pembrolizumab + Lenvatinib</i>	Nil
<i>Pembrolizumab monotherapy</i>	Nil
<i>Radiotherapy only</i>	Nil
<i>Sunitinib</i>	8
<i>Temsirolimus</i>	Nil
<i>Tivozanib</i>	Nil
<i>Other active systemic anti-cancer therapy</i>	Nil
<i>Palliative care only</i>	Nil

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- *Cobimetinib*
- *Dabrafenib*
- *Dabrafenib AND Trametinib*
- *Dacarbazine*
- *Encorafenib AND Binimetinib*
- *Ipilimumab*
- *Ipilimumab AND Nivolumab*
- *Nivolumab*
- *Pembrolizumab*
- *Trametinib*
- *Vemurafenib*
- *Vemurafenib AND Cobimetinib*
- *Other active systemic anti-cancer therapy*
- *Palliative care only*

Answer:

Treatment	Total
<i>Cobimetinib</i>	Nil
<i>Dabrafenib</i>	≤5
<i>Dabrafenib AND Trametinib</i>	13
<i>Dacarbazine</i>	Nil
<i>Encorafenib AND Binimetinib</i>	Nil
<i>Ipilimumab</i>	Nil
<i>Ipilimumab AND Nivolumab</i>	9

<i>Nivolumab</i>	10
<i>Pembrolizumab</i>	64
<i>Trametinib</i>	Nil
<i>Vemurafenib</i>	Nil
<i>Vemurafenib AND Cobimetinib</i>	Nil
<i>Other active systemic anti-cancer therapy</i>	≤5
<i>Palliative care only</i>	Nil